AIPLA Rapid Response Webinar

Home

 

 

In This Section

AIPLA Rapid Response Webinar: USPTO Sequence Listing Rules

June 29 to 30, 2022

Location

Virtual

Credits

No CLE

Registration

Fee: Free
Registration closes June 29, 2022 at 12:00 PM

Register Now

Standard ST.26, requiring XML formatting, will go into effect worldwide on Friday, July 1. The United States Patent and Trademark Office (USPTO) is adopting new rules to implement this standard as recently published in the Federal Register. Beginning July 1, sequence listings filed electronically in XML format must be filed via the USPTO’s Patent Center.

Join us for a Rapid Response webinar focused on the new USPTO Sequence Listing rules. Learn about the new process BEFORE it goes into effect July 1. We will be joined by speakers from the USPTO and WIPO, as well as experienced practitioners to provide guidance on how to submit a compliant sequence listing in U.S. patent applications and Patent Cooperation Treaty (PCT) applications.

Moderator:  Carla Mouta-Bellum, Arrigo, Lee, Guttman & Mouta-Bellum, LLP, Washington, DC

Confirmed Speakers:

Kathleen Kalafus, USPTO
Hanna Kang, WIPO
Alice Martin, Barnes &Thornburg, LLP, Chicaog, IL - Chair, AIPLA Biotechnology Committee
Mary Till, USPTO

PRESENTATION SLIDES:

USPTO Sequence Listing Presentation

WIPO Sequence Listing Presentation

Practitioner Q&A Presentation

LINK TO RECORDING WILL BE POSTED HERE

Add to:

 

 

News

  • TermDisc-Comments-March21-logo AIPLA Comments on CNIPA Draft Measures for Prioritized Patent Examination

    April 1, 2026

    Arlington, VA. March 30, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the China National Intellectual Property Administration (CNIPA) regarding the Draft Measures for the Administration of Prioritized Examination of Patents.
  • AIPLA Files Amicus Brief in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc

    March 31, 2026

    Arlington, VA. March 27, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the Supreme Court in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889. AIPLA urges the Court to affirm the Federal Circuit’s application of the established Iqbal/Twombly pleading standard and inducement law in reviewing Hikma’s motion to dismiss Amarin’s claim that Hikma’s conduct, in combination with its “skinny label,” induced infringement of Amarin’s patented treatment methods.
  • Supreme Court Issues Unanimous Decision in Cox Communications, Inc. v. Sony Music Entertainment

    March 25, 2026

    On March 25, 2026, the Supreme Court issued a unanimous decision in Cox Communications, Inc. v. Sony Music Entertainment. The majority opinion limits contributory liability to situations where a party intended that its service be used for infringement, either by affirmatively inducing infringement or by selling a service tailored to infringement. A concurring opinion by Justice Sotomayor argues that the material contribution test should be retained, and that other forms of secondary liability can be found, which is consistent with the position asserted by AIPLA in its amicus brief filed on September 5, 2025. To read the opinion of the Court, please click here.
  • Writing AIPLA Comments on the Draft Trademark Law of the People’s Republic of China

    March 23, 2026

    Arlington, VA. February 9, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the Legislative Affairs Commission of the Standing Committee of the National People’s Congress regarding the latest Draft Trademark Law of the People’s Republic of China. AIPLA recognized the NPC’s efforts to streamline trademark procedures, strengthen protection, and address abusive and bad-faith filing practices.
  • AIPLA Files Amicus Brief in USAA v. PNC Bank

    March 3, 2026

    Arlington, VA. March 2, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief with the Supreme Court in USAA v. PNC Bank, N.A., No. 25-853, in support of USAA’s petition for certiorari, urging the Court to provide much-needed guidance to address the unpredictable and overly broad application of the judicial exceptions to patent-eligible subject matter under 35 U.S.C. § 101, particularly the “abstract idea” exception.